"A PHASE III, OPEN-LABEL, PROSPECTIVE, MULTICENTER STUDY TO ASSESS EFFICACY, SAFETY AND PHARMACOKINETICS OF KEDRION INTRAVENOUS IMMUNOGLOBULIN (IVIG) 10% IN PRIMARY IMMUNODEFICIENCY DISEASE (PID) PATIENTS."

Registry ID

KIG10_US3_PID01

Source registry

HEALTH_CANADA

Status

Closed

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

KEDRION S.P.A.

Completion date

2020-02-12

Last update

2019-04-03

Conditions

• PRIMARY IMMUNODEFICIENCY DISEASES

Related clinical trials

• PHASE IB OPEN LABEL BASKET TRIAL OF RAY121 TO INHIBIT CLASSICAL COMPLEMENT PATHWAY IN IMMUNOLOGICAL DISEASES (RAINBOW TRIAL)
• CLINICAL PHASE III STUDY TO MONITOR THE SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES, INCLUDING (BUT NOT LIMITED TO) THOSE WHO HAVE COMPLETED THE SCGAM 01 TRIAL
• AN OPEN-LABEL, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND PHARMACOKINETICS OF IGSC 20% ADMINISTERED FOR 6 MONTHS IN SUBJECTS WITH PRIMARY IMMUNODEFICIENCY
• CLINICAL PHASE III STUDY TO EVALUATE THE PHARMACOKINETICS, EFFICACY, TOLERABILITY AND SAFETY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM 16.5%) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES
• REDUCING-INTENSITY CONDITIONING FOR CHILDREN AND ADULTS WITH HEMOPHAGOCYTIC SYNDROMES OR SELECTED PRIMARY IMMUNE DEFICIENCIES (RICHI)

View on source registry